echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > FDA revokes emergency use authorization for Eli Lilly's new crown antibody drug

    FDA revokes emergency use authorization for Eli Lilly's new crown antibody drug

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Editor: Wu Bin

    As the new crown virus continues to mutate, the US pharmaceutical giant accidentally "lay the gun".
    On Friday, the US Food and Drug Administration (FDA) revoked the emergency use authorization of Eli Lilly's new crown antibody drug bamlanivimab.

    The FDA explained in the statement that because of the increase in mutant viruses that are resistant to bamlanivimab, only using the drug to treat patients with new coronary pneumonia infection "the risk of treatment failure is increasing.
    " The benefits of using the drug no longer exceed the risks.
    Does not meet the emergency use authorization conditions.

    The FDA explained in the statement that because of the increase in mutant viruses that are resistant to bamlanivimab, only using the drug to treat patients with new coronary pneumonia infection "the risk of treatment failure is increasing.
    " The benefits of using the drug no longer exceed the risks.
    Does not meet the emergency use authorization conditions.

    On November 9th last year, Eli Lilly’s new crown antibody drug bamlanivimab was authorized by the FDA for emergency use, and it became the first new crown antibody drug under development that received emergency use authorization.
    On January 21 this year, Eli Lilly said that the antibody drug bamlanivimab developed by the company has been shown to effectively reduce the risk of the elderly and employees in long-term care facilities becoming symptomatic infections.

    It is worth noting that before the FDA announced on Friday that the emergency use authorization of Eli Lilly's new crown antibody drug was revoked, Eli Lilly had already admitted that due to some mutant viruses circulating in the United States, the effect of treatment with bamlanivimab alone has declined, and Eli Lilly will Focus on promoting the cocktail therapy of bamlanivimab and the company's second antibody drug etesevimab.

    Although the emergency authorization of the new crown antibody drug bamlanivimab has been revoked, the FDA emphasized that the REGEN-COV antibody cocktail therapy, Eli Lilly bamlanivimab and etesevimab cocktail therapy are still available.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.